Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Amanda Dendis

Nurse Practitioner Fort Myers, FL Nurse Practitioner

NPI 1881160695 CMS profile 11133253

12670 Whitehall Dr, Fort Myers, FL 33907

Open in the dashboard

General payments

$4,955

261 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Amanda Dendis of Fort Myers, FL is reported in the CMS Open Payments database as having received $4,955 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $538 20
2022 General $2,408 124
2021 General $2,010 117

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Dendis
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Dendis were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Dendis Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,010 $135 $40–$426 $132
2022 $2,408 $152 $48–$470 $149
2023 $538 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $554 29 payments
  2. ACADIA Pharmaceuticals Inc $301 25 payments
  3. Amgen Inc. $299 16 payments
  4. UCB, Inc. $296 8 payments
  5. Biohaven Pharmaceuticals, Inc. $295 22 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $294 22 payments
  7. Teva Pharmaceuticals USA, Inc. $156 8 payments
  8. Genzyme Corporation $147 7 payments
  9. Sumitomo Pharma America, Inc. $145 2 payments
  10. Argenx US, Inc. $134 4 payments
  11. Other $2,334 118 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $4,947 259 payments
  2. Education $9 2 payments
Products named General payments · program years 2021–2023
  1. NURTEC ODT $590 44 payments
  2. UBRELVY $386 19 payments
  3. Briviact $260 7 payments
  4. NUPLAZID $201 19 payments
  5. AIMOVIG $165 9 payments
  6. APTIOM $145 2 payments
  7. VYVGART $134 4 payments
  8. QULIPTA $130 8 payments
  9. ENROUTE Transcarotid Stent $128 1 payment
  10. ENROUTE Transcarotid Neuroprotection System $128 1 payment
  11. Other $2,773 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$26,923

Medicare's payments for the services billed

Medicare patients

230

Average age 78

Services billed

356

114 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 50%
Chronic kidney disease 49%
Diabetes 44%
Depression 43%
Atrial fibrillation 41%
Heart failure 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record